March 16, 2020 / David Jagielski Johnson & Johnson (NYSE:JNJ) released a statement on Monday that said there wasn’t sufficient evidence to suggest its HIV drug darunavir (DRV) can effectively treat COVID-19, the disease caused by the novel coronavirus. The company said HIV drugs are being considered as possible treatment options largely due to limited and “unpublished …